Opus Genetics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Opus Genetics reported Q2 2026 cash of $88.8M (June 30) with runway into 2029. OPGx-BEST1 Cohort 1 topline data expected September 2026; OPGx-LCA5 enrollment completed with dosing planned Q4 2026; RDH12, MERTK, and RHO programs entering/advancing clinical testing in 2026–2027. Q2 net loss was $8.1M ($0.14 diluted per share) vs. $7.4M in Q2 2025; R&D expenses increased to $11.2M from $6.0M YoY due to higher manufacturing and clinical costs. License revenue declined to $0.8M from $2.9M (Viatris partnership reimbursement lower).
Why this rating
Pipeline progress and extended cash runway are positive; however, rising R&D burn ($11.2M vs. $6.0M), declining revenue ($0.8M vs. $2.9M), and negative stockholders' equity ($-13M vs. +$15.3M six months ago) are concerning. $88.8M cash is ~2× market cap but must fund operations, clinical trials, and manufacturing. Not immediately transformational but material execution risks.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.